Technology

MBS8 is a second-generation systemic TLR7 agonist designed to overcome the limitations of first-generation compounds, which were typically administered as free small molecules and limited by toxicity.

MBS8 differentiates versus first generation agonists by combining a potent TLR7 agonist with a proprietary lipid nanoparticle formulation. This micelle-based delivery enables direct targeting to immune cells after systemic delivery while maintaining systemic tolerability.

Following intravenous administration, MBS8 is taken up by immune cells and promotes recruitment of immune cells, including CD8 T cells, leading to restoration of tumor-specific immunity.

The result is conversion of immune “cold” tumors into inflamed, “hot” tumors capable of responding to immunotherapy. Preclinical data demonstrate durable immune memory and complete tumor remissions in multiple models.

Todays challenges in cancer treatment

The major challenges for cancer treatment today is to improve treatment and survival of patients with advanced, recurrent and metastatic disease.

Checkpoint inhibitors have transformed melanoma care but 40-50% of responding patients relapse due to secondary resistance.to checkpoint therapy with poor treatment options.

Most metastatic tumors suppress immune infiltration and disable tumor-specific T cells, and there is no broadly effective therapy designed specifically to reverse this resistance.

Our solution

Our technology provides a solution to this challenge through renewed recruitment of T-cells and other immune cells to the tumor tissue to reactivate tumor cell killing.